Dr. Mudad on RELAY Trial for EGFR-Mutant NSCLC

Video

Raja Mudad, MD, FACP, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non–small cell lung cancer.

Raja Mudad, MD, FACP, a founding partner at Florida Precision Oncology, discusses the RELAY trial and using doublet therapy to treat EGFR-mutant non—small cell lung cancer (NSCLC).

The RELAY trial examined adding ramucirumab (Cyramza) to erlotinib (Tarceva) to see if the agents work better as a combination in patients with NSCLC who have an EGFR mutation. The progression-free survival (PFS) between single-agent erlotinib plus ramucirumab versus erlotinib plus placebo was 19.4 months versus 12.4 months, respectively, explains Mudad. Additionally, there was a significant elongation of PFS in single-agent erlotinib that is not as long as what would be seen with single-agent osimertinib (Tagrisso), according to Mudad.

Toxicity for the combination regimen had more toxicity related to VEGF inhibition, such as bleeding or thrombosis. Mudad believes the job of the physician is to find the ideal way of combining and sequencing [agents] to do better than single agents. One possibility is to start with a second- or first-generation EGFR inhibitor plus a VEGF inhibitor and follow that up with a third-generation EGFR inhibitor, says Mudad. Current trials are looking at osimertinib (Tagrisso) combined with ramucirumab or bevacizumab (Avastin), concludes Mudad.

Related Videos
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
© 2024 MJH Life Sciences

All rights reserved.